NOXXON Pharma N.V.
PAR: ALNOX.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Aram Mangasarian
- Employees
- 13
- Headquarters
- Berlin, Germany
- IPO year
- 2018
- Website
- https://www.noxxon.com
Loading ALNOX…
Loading profile data…Frequently asked questions about ALNOX
What does NOXXON Pharma N.V. (ALNOX.PA) do?
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination ther...
Where does ALNOX.PA trade?
NOXXON Pharma N.V. (ALNOX.PA) trades on the Euronext Paris.
What sector is ALNOX.PA in?
NOXXON Pharma N.V. (ALNOX.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NOXXON Pharma N.V.?
Aram Mangasarian is the chief executive officer of NOXXON Pharma N.V. (ALNOX.PA).
Where is NOXXON Pharma N.V. headquartered?
NOXXON Pharma N.V. is headquartered in Germany.
Does ALNOX.PA pay a dividend?
NOXXON Pharma N.V. (ALNOX.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALNOX.PA go public?
NOXXON Pharma N.V. (ALNOX.PA) completed its initial public offering in 2018.